PHARM.ASPHARM.ASAMS
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank46
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P46
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -1.31% |
| Q2 2025 | 12.08% |
| Q1 2025 | -5.23% |
| Q4 2024 | 7.66% |
| Q3 2024 | -3.98% |
| Q2 2024 | 16.79% |
| Q1 2024 | 57.99% |
| Q4 2023 | -43.65% |
| Q3 2023 | -0.77% |
| Q2 2023 | 33.89% |
| Q1 2023 | 43.41% |
| Q4 2022 | -11.76% |
| Q3 2022 | -14.48% |
| Q2 2022 | -2.89% |
| Q1 2022 | -12.73% |
| Q4 2021 | 0.00% |
| Q2 2021 | 30.13% |
| Q1 2021 | -23.18% |
| Q4 2020 | 35.51% |
| Q3 2020 | 9.05% |
| Q2 2020 | 3.39% |
| Q1 2020 | 51.97% |
| Q4 2019 | -35.66% |
| Q3 2019 | -17.47% |
| Q2 2019 | 83.93% |
| Q1 2019 | -52.81% |
| Q4 2018 | 93.49% |
| Q3 2018 | -4.28% |
| Q2 2018 | -3.63% |
| Q1 2018 | 0.49% |
| Q4 2017 | 44.47% |
| Q3 2017 | -10.78% |
| Q2 2017 | 8.98% |
| Q1 2017 | 33.51% |
| Q4 2016 | -18.62% |
| Q3 2016 | 27.01% |
| Q2 2016 | -13.29% |
| Q1 2016 | 7.47% |
| Q4 2015 | -8.17% |
| Q3 2015 | -4.14% |